Coronavirus vaccine illustration

Good news, trial of Corona-PICU antibody response Virus vaccine

The Corona virus vaccine trials (Covid-19) have triggered antibody responses and demonstrated safety in early-stage human tests in Serika (USA).

The result has been praised as "good news" by Dr. Anthony Fauci, the leading infectious disease expert in America.

On Tuesday (14/7/2020), the researchers reported findings from the first 45 healthy adults who received the experimental vaccine Moderna INC last March, indicating it gave hope for increasing antibodies.

The early volunteers developed the antidote in their bloodstream, which was the key to blocking the infection, at a level comparable to that found in the survivors of the Covid-19, a team of researchers reporting in the New England Journal of Medicine.

"This is an essential element that is required to move forward with a trial that can actually determine whether the vaccine protects against infection," said Dr. Lisa Jackson, who led the research on the reported Independent, thursday (16/7/2020).

Dr. Fauci, director of the National Institute of Allergies and Infectious diseases, whose researchers developed the Moderna vaccine candidate, said that if the vaccine can trigger a response comparable to a natural infection, it is the winner.

"That's why we are very pleased with the results," he said.

No research volunteers experience serious side effects, but more than half report mild or moderate reactions such as fatigue, headache, chills, muscular pain or pain at the injection site. This is more likely to occur after the second dose and in the person who gets the highest dose.

Moderna was the first to start a human vaccine test for viruses on March 16.

In last April, Phase 1 trials aimed to ensure safe treatment and help determine the effective dose, expanded to include adults over the age of 55years, who are more at risk of serious illness.

Moderna said, will be following a volunteer for a year to find side effects and examine how long the immunity lasts.

The corona virus vaccine trials will initiate the most important step around late July, where the study of 30,000 people to find out if the injections were really strong enough to protect against corona viruses.

Nearly two dozen possible Covid-19 vaccines are in various stages of testing around the world.

The University of Oxford potential vaccine is already in the human trials of the third phase of the large scale to assess whether it can protect against Covid-19, but the developers have not reported the results of phase 1 that will indicate whether it is safe and whether it is encouraging or not. Immune response.

The developers of vaccines said that they were driven by the immune response they saw in the trial so far and hoped to be able to publish phase 1 data at the end of July.

Researchers at Imperial College London started a second human trial in the UK into a coronavirus vaccine last month.

Source: http://tiny.cc/3uehnz